

Anidulafungin

Reserve Antimicrobial											
See CUH Antimicrobial Guidelines on Eolas for further information											
CAUTION: Anidulafungin is administered as a loading dose followed by a maintenance dose . Double check the correct dose has been prescribed.											
Form & Storage	Vial containing 100mg dry powder	Store at 2–8°C in original packaging.									
Reconstitution	Reconstitute each vial with 30mL WFI and allow to stand for up to five minutes. Dilute further before administration.										
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%										
Administration	IV Infusion <table border="1" data-bbox="579 882 1334 983"> <thead> <tr> <th>Dose</th><th>Volume infusion fluid</th><th>Infusion time</th></tr> </thead> <tbody> <tr> <td>100mg</td><td>100mL</td><td>90 mins</td></tr> <tr> <td>200mg</td><td>200mL</td><td>3 hours</td></tr> </tbody> </table> <p>Loading dose 200mg (Day 1 only) Withdraw 50mL from 250mL infusion bag of compatible fluid and discard. Add 200mg (60mL) to remaining 200mL. Administer over 3 hours.</p> <p>Maintenance dose 100mg Add 100mg (30mL) to 100mL of compatible fluid. Administer over 90 minutes.</p> <p>Final concentration of 0.77mg/mL. Recommended that rate of infusion does not exceed 1.1mg/min (1.4mL/min) when reconstituted and diluted as per instructions.</p>		Dose	Volume infusion fluid	Infusion time	100mg	100mL	90 mins	200mg	200mL	3 hours
Dose	Volume infusion fluid	Infusion time									
100mg	100mL	90 mins									
200mg	200mL	3 hours									
Extravasation	Anidulafungin has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely using a recognised phlebitis scoring tool. Re-site cannula at first signs of inflammation.										
Additional Information	<ul style="list-style-type: none"> Infusion-related reactions have been reported with anidulafungin. Do not exceed the maximum infusion rate. Anidulafugin is usually prescribed as a Loading dose followed by a Maintenance dose. 										

Information provided relates to Ecalta® (Pfizer) and Anidulafungin (Teva and Rowex)

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542